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Abstract 
Purpose: Our study examines the impact of breast cancer-related lymphedema on women’s work and career. Our 
research addresses a significant knowledge gap regarding the additional impact of lymphedema on breast cancer 
survivors.
Methods: An online national survey was conducted with 361 women who either had breast cancer without 
lymphedema (Group 1, n = 209) or breast cancer with lymphedema (Group 2, n = 152). Participant recruitment was 
supported by the Breast Cancer Network Australia and the Australasian Lymphology Association.
Results: Both breast cancer and lymphedema had a significant negative influence on women’s work and career. 
Respondents reported changes in employment resulting from stress and/or physical impairment, which affected 
attendance and work performance. The perceived negative impact of breast cancer on respondents’ work and 
career was noticeably greater in Group 2 (63 %) than Group 1 (51 %) (p = 0.03). Of the participants who were in 
paid employment at some time (either at diagnosis of lymphedema or at the time of the survey (n = 103), 43 (42 %) 
indicated that lymphedema impacted their work performance. The impact of lymphedema on work was incremental 
with increased severity of lymphedema (range 22–75 %). The annual number of days off work for subclinical/mild 
lymphedema participants was 1.4 versus 8.1 days for moderate or severe participants (p = 0.003).
Conclusions: This study identifies an additional detrimental effect of lymphedema on women’s work and career 
over and above the initial impact of breast cancer and provides empirical evidence for future prospective studies and 
policy improvement.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
As the number of breast cancer survivors increases with 
better treatments, the number of patients with long-
term side-effects including fatigue, cognitive problems, 
sexual dysfunction and fear of recurrence is also grow-
ing (Beckjord et  al. 2014). Another feared side-effect is 
lymphedema caused by surgery, radiation therapy, and 
some chemotherapy treatments that increase the risk of 
fluid accumulation from lymphatic disruption (Cornish 
et al. 2000; Kilbreath et al. 2013). Lymphedema can cause 
pain, increase the risk of cellulitis, and limit a patient’s 
activities of daily living including, bathing, dressing, 
grooming and domestic tasks (Tretbar et al. 2008).
Lymphedema may present immediately or many years 
after breast cancer treatment. The mean interval from 
treatment to the development of mild arm lymphedema 
is about 18 months with one in three patients progress-
ing from mild to severe arm lymphedema within 5 years 
(Bar et  al. 2010, 2012). The incidence of breast cancer 
related lymphedema (BCRL) is variable and often under-
reported due to a lack of standardised diagnostic crite-
ria (Armer et al. 2013; Bernas 2013; Sander et al. 2002). 
However, recent studies have demonstrated that rates 
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range from 5  % with conservative treatment (lumpec-
tomy or wide local excision and sentinel node biopsy) 
alone, to greater than 20–50  % in cases with axillary 
node dissections, regional irradiation, and possibly tax-
ane based chemotherapy (Hayes et al. 2005; Hayes 2008; 
Lucci et al. 2007; DiSipio et al. 2013; Swaroop et al. 2015). 
Age, obesity, nodal radiation, a post-operative seroma or 
infection further increase the risk (Monleon et al. 2015; 
Shaitelman et al. 2015).
Previous studies have examined the impact of cancer 
treatment on work and most of these have been on breast 
cancer. In a 2011 meta-analysis, 28 of 64 studies reported 
data about rates of employment or return to work after 
treatment. Overall, an average 63.5  % of participants 
(range 24–94 %) managed to return to work but the rate 
steadily increased as the period of time after cancer treat-
ment increased. This ranged from, on an average, 40 % at 
6  months post diagnosis to 62  % at 12  months, 73  % at 
18 months, and to 89 % at 24 months after cancer diagno-
sis (Mehnert 2011).
While the literature that examines the impact of 
lymphedema on individuals’ employment is limited, 
it does report some consistent findings (Bulley et  al. 
2013; Gartner et al. 2010; Johansson et al. 2003; Fu et al. 
2008). A common theme concerns whether the individ-
ual remains in employment as well as how many hours 
they choose to work. Exiting the workforce or reducing 
hours may occur for a variety of reasons, such as: pain 
and restricted arm mobility affecting the ability to com-
plete tasks; infections causing absences; restriction on 
the wearing of compression sleeves or gloves in specific 
occupations and reduced mental health, worry about job 
security due to inability to accomplish assigned respon-
sibilities, depression especially when one’s job responsi-
bilities are impacted and feeling helpless due to loss of 
independence by having to rely on others to accomplish 
house work or job responsibility (Fu et al. 2013) (REF).
To that end, Bulley et al. (2013) examined the physical 
and psychosocial burden associated with lymphedema, 
noting that participants with lymphedema experienced 
greater burden than those without lymphedema with a 
doubling in the rate of stopping work or reducing hours. 
The importance of employment has also been highlighted 
in medical literature examining individuals’ Health 
Related Quality of Life (HR-QOL) with scholars empha-
sising the adjustments individuals have had to make to 
return to work post-diagnosis, such as changing employ-
ers, reducing hours or modifying their work space to 
accommodate their aching limbs (Fong et al. 2015).
No previous study has specifically explored the impact 
of the severity of lymphedema on work and career. With 
this in mind we undertook a cross-sectional quantita-
tive study to further the scholarship on the impact of 




A survey of breast cancer survivors with and without 
lymphedema was undertaken Australia-wide. Partici-
pants were asked to complete an electronic survey exam-
ining the impact of lymphedema over and above breast 
cancer on their work, social life, self-esteem, body image 
and finances.
Study population
Due to the limited knowledge on the socio-economic 
impact of lymphedema, an exploratory qualitative study 
was initially undertaken, which entailed interviews with 
30 individuals—10 with primary lymphedema and 20 
with secondary lymphedema. In those interviews, we 
explored two domains: employment and home-life. In 
addition, interviewees were asked to explain the treat-
ment costs they have had to pay for over the course of 
their condition and how these affected their decision-
making processes regarding treatment. This stage, to be 
reported elsewhere, allowed us to refine our conceptual 
framework and theory to test in the second, quantitative 
phase, reported here.
During the second phase, we utilized survey-method-
ology to collect extensive data on the impact that living 
with secondary lymphedema has on cancer-survivors’ 
work life. The survey instrument is available on request. 
A complexity that was addressed in the study was how 
to differentiate the impact of a diagnosis of lymphedema 
over and above a diagnosis of breast cancer. The survey 
instrument therefore had two sections looking at the 
impact of lymphedema first (if present) and then breast 
cancer for all patients.
Individuals eligible for participation were: female; over 
18 years of age; previously diagnosed with primary stage 
I, II or III breast cancer who had completed treatment at 
least 1  year prior to recruitment and fluent in English. 
Individuals who fulfilled these criteria only became the 
control group. In addition, we targeted individuals who 
fulfilled all the criteria above, but with a confirmed diag-
nosis of lymphedema, either by a doctor or lymphedema 
therapist, including participants with subclinical 
lymphedema diagnosed with bioimpedance spectroscopy 
(L-Dex) alone; who had sought therapist advice; and/or 
were wearing compression garments. Participants com-
pleted the study questionnaire online.
Women previously diagnosed with breast cancer were 
approached for study participation through an Austral-
ian community-based breast cancer consumer organiza-
tion, the Breast Cancer Network of Australia (BCNA). 
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An e-mail invitation was sent by a contact person within 
the BCNA to members who had previously agreed to 
receive notifications about research studies. Participants 
with lymphedema were also asked to consider the study 
through the Australasian Lymphology Association (ALA) 
and by notices in the clinics of authors (JB, LK and HM). 
It was the responsibility of the women who received the 
e-mail to determine their eligibility for the study. A total 
of 361 women agreed to participate. Following online 
consent, participants anonymously completed the ques-
tionnaire that took approximately 30  min to complete. 
The conduct of this research was approved by the Mac-
quarie University Human Research Ethics Committee.
Definitions
We asked a screening question in order to classify our 
respondents’ lymphoedema stage. We asked them to 
reflect on their condition for the last month and first, 
report on its severity by choosing one of the following 
categories.
  • No problem: no noticeable swelling. We later termed 
this category as sub-clinical lymphedema detected by 
a therapist or clinician using girth measures or bio-
impedance spectroscopy (L-Dex).
  • Mild lymphedema: soft swelling that is not obvious 
to others and comes and goes.
  • Moderate lymphedema: swelling with occasional 
hardness in some areas that is obvious to others and 
is always present.
  • Severe lymphedema: profuse swelling with thickened 
skin, constant hardness, and a very large, heavy arm that 
is extremely obvious to others and is always present.
Statistical analysis
Participants with breast cancer were asked specific 
questions about how their cancer affected the follow-
ing domains: (1) Work/career; (2) Family Life (3) Social/
Leisure (4) Self Image and (5) Feeling about Self. For 
participants given a diagnosis of lymphedema, in addi-
tion to the above domains, data was also collected on 
the impact of lymphedema on employment, cost of see-
ing therapists and the cost of compression sleeves. Data 
collection occurred between November 2014 and March 
2015 using Qualtrics. All p values are two-sided using the 
two-sample t test, unless otherwise specified. This paper 
will focus on the impact of lymphedema over and above 
breast cancer on work and career.
Results
Of 361 participants, 209 (58  %) had breast cancer (BC) 
(Group 1) and 152 (42  %) had a diagnosis of BC and 
lymphedema (BC  +  LE) (Group 2). The severity of 
lymphedema was “not noticeable” in 14 (9  %), mild in 
77 (51  %), moderate in 55 (36  %) and severe in six par-
ticipants (4  %). Ninety-two of 209 (44  %) BC partici-
pants were aged under 55 compared to 54 of 152 (34 %) 
of BC + LE participants (p = 0.105). The duration since 
completion of all breast cancer treatment was <5  years 
for 75 % of the BC group and 56 % for the BC + LE group 
(p < 0.001). The time since the onset of lymphedema was 
<5  years in 65  % of the BC  +  LE group. Other demo-
graphic features of the study participants are shown in 
Table 1.
Both breast cancer and lymphedema had a significant 
impact on a person’s ability to work. Breast cancer had 
an impact on the ability to work in 51 % of participants 
in Group 1 but participants with lymphedema perceived 
their breast cancer diagnosis to have had a greater impact 
on their work (63 %) (p = 0.03) (Fig. 1). Of the 103 Group 
2 participants who were in paid employment at some time 
(either at diagnosis of lymphedema or at the time of the 
survey), 43 (42 %) indicated that lymphedema impacted 
their work performance. The impact of lymphedema on 
work increased as the severity of the condition increased, 
ranging from 22  % for subclinical lymphedema to 75  % 
for participants with severe lymphedema. The average 
time off work annually as sick or unpaid leave was less 
than 2  days (range 0–28  days) for subclinical or mild 
lymphedema (n = 50) and 8 days (range 0–54) for mod-
erate or severe lymphedema (n = 28) (p = 0.003).
Figure 2 explores some of the reasons and the extent to 
which work performance was affected in Group 2. Of the 
43 participants, 40 % reported attending work when they 
were unwell for fear of losing their job (a phenomenon 
which Aronsson et al. (2000) termed “presenteeism”) and 
47 % reported not being able to work longer hours. These 
numbers correspond to 17 and 20  % of the 103 partici-
pants who were employed.
Table  2 shows employment transitions for the two 
study groups. At the point of diagnosis, 77 % of partici-
pants in the Group 1 were in paid employment drop-
ping to 59  % at the time of the survey (p =  0.025). For 
Group 2 the numbers drop from 63 to 51 % respectively 
(p = 0.165). The main reason behind this transition was 
an increased percentage of retirements (Group 1: 27 % vs 
Group 2: 37 %, p = 0.044).
We explored how often and why employment changed 
after a diagnosis of breast cancer or lymphedema 
(Table  3). Of the participants who were employed in 
Group 1, just over half (51  %) indicated that their con-
ditions of employment changed mostly due to reduced 
working hours. At the time of diagnosis of lymphedema, 
about one in five (19 %) in Group 2 indicated that their 
employment conditions had changed again mainly due to 
reduced hours.
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Of the 103 Group 2 participants who were in paid 
employment, 54 (52.4 %) did not disclose their diagnosis 
of lymphedema to their supervisor and 40 (38.8 %) did not 
disclose their diagnosis of lymphoedema to their cowork-
ers (p =  0.147). Table  4 shows the participants’ percep-
tions of how their peers and coworkers reacted to their 
diagnosis of lymphedema. Although there was a lower rate 
of disclosure to supervisors (47.6 %) than peers (61.2 %), 
once disclosed there was no significant difference in the 
type of information that was disclosed. Although the rate 
of discrimination at work was thought to be higher in the 
BC + LE group (14 %) than the breast cancer group (5 %), 
this did not reach statistical significance (0.07).
Discussion
Lymphedema is a feared complication of breast cancer 
and impacts physical, functional, psychological and social 
well-being of participants after breast cancer treatment. 
Yet, existing scholarship is in early stages of development 
regarding many aspects of this condition. Our first in-
depth cross-sectional study, shows that, when compared 
to breast cancer survivors without lymphedema, individ-
uals living with lymphoedema are worse off in terms of 
work and career.
In a previous meta-analysis of the impact of a diagnosis 
of cancer on work, a non-supportive work environment, 
manual work, cancer types associated with an unfavoura-
ble prognosis, the presence of fatigue and physical symp-
toms, and perceived employer discrimination because 
of cancer and treatment were reported as barriers for 
returning to work (Mehnert 2011). Our study high-
lights that sick leave, in its current form, is falling short 
for individuals living with chronic illnesses: 43 of 103 
employed participants (42 %) reported that lymphedema 
had affected their work performance with 17  % of the 
total reporting that they have turned up at work on days 
they feel unwell either to avoid a low attendance record, 
or because they fear for their job security (Fig. 1).
Few studies, however have examined the impact of 
lymphedema over and above the diagnosis of breast 
cancer. For example, Johansson et  al. (2003) explored 
twelve working women’s experiences of lymphedema and 
reported that typing or long periods without rest became 
difficult or even impossible. Fu et  al. (2008) examined 
the impact of lymphedema in the workplace among five 
female breast-cancer survivors and found that it was a 
particular problem for women who needed to lift objects 
at work. Fears regarding job security were also reported 
especially in cases where the employer was unsupportive. 
In an updated study Fu (2008) found that the majority 
of women (12 out 22) whose jobs involved heavy lifting 
and constant use of the affected arm and hand were from 
Table 1 Demographics of participant group







p value209 (%) 152 (%)
Age at time of survey
 <55 years 44.0 35.5 NS
 ≥55 years 56.0 64.5
Country of birth
 Australia 80.4 80.3 NS
 United Kingdom 9.6 8.6
 New Zealand 4.8 4.6
 Other 5.2 6.5
Marital status
 Single, never married 9.1 6.6 NS
 Married, de facto 75.6 80.3
 Separated/divorced 12.9 11.8
 Widowed 2.4 1.3
Primary carer
 No 65.6 57.9 NS
 Yes 18.2 22.4
 Yes 5.7 3.3
 Yes 3.3 5.9
 Yes 7.2 10.5
Years since treatment of breast cancer
 <5 years 74.6 55.9 0.000
 ≥5 years 25.4 44.1
Years since diagnosis of lymphedema
 <5 years – 65.1 –
 ≥5 years 34.9
Paid employment at 




 Manufacturing 2.5 0.7 NS
 Wholesaling 2.0 –
 Retailing 8.1 9.6
 Accommodation 1.0 1.4
 Cafés, restaurants 1.5 1.4
 House construction 0.5 1.4
 Health service 20.7 15.1
 Education 22.7 27.4
 Community care 
service
4.5 5.5
 Telecommunication 0.5 1.4
 Financial services 3.0 6.8
 Other 32.8 29.5
Total household income
 ≤$45,000 20.6 15.1 NS
 >$45,000–<$100,000 29.2 31.6
 ≥100,000 32.1 34.9
 Prefer not to say 18.2 18.4
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Fig. 1 The relationship between breast cancer, lymphedema and lymphedema severity on their impact on the ability to work. Numbers in paren-
theses represent the total number of participants who were in paid employment within the various subgroups
Fig. 2 Reasons why employed participants with lymphoedema were affected at work. Percentages with parentheses are of the 103 total and with-
out parentheses are of the 43 participants whose diagnosis of lymphedema affected them at work
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either African American or Chinese American groups. 
It was noted that this group of women needed their jobs 
as a source of financial income or medical insurance and 
not only suffered the physical and functional impact of 
lymphoedema on their work, but had to endure con-
stant emotional distress created by their supervisors or 
employers who had no understanding of breast cancer 
survivors with lymphoedema. Based on these findings we 
argue that policy makers should pay further attention to 
the fact that sick leave is designed under an acute illness 
framework, which assumes the individual will eventually 
get better.
In a study of 67 participants with perceived 
lymphedema who were working, Mehnert (2011) found 
that 25 % had to stop their employment and 10 % (total 
35 %) had to reduce their hours compared to 11 and 8 % 
of 247 participants (total 19  %) without lymphedema. 
Their study was similar to ours except they recruited 
from a specific follow-up clinic rather than a nationwide 
survey performed in our setting. In our study, of the 109 
participants with BC + LE, 22 (20 %) had to stop work-
ing, 24  % had to reduce hours because of their breast 
cancer (total, 44 %), compared to 16 and 23 % of the 166 
participants with BC alone (total, 39 %).
Gartner et  al. (2010) also examined the impact of 
lymphedema on women’s daily activities at work, with 
36  % of the sample indicating that it had affected their 
work. Specifically, 47 % reported light work above shoul-
der level as problematic, 27 % reported daily activity with 
involvement of shoulder rotation as troublesome while 
heavy work was associated with difficulties for 1884 
women (59 %).
Finally, Fantoni et al. (2010) studied 379 women with 
breast cancer aged up to 60 years old, who were work-
ing at the time of diagnosis using a 45-item question-
naire. During a median follow-up of 36 months, 82.1 % 
of the 379 women who had worked before their diag-
nosis returned to work after a median sick leave of 
10.8 months. Older age, lower educational level, chem-
otherapy, radiotherapy, lymphoedema, psychological 
or organizational self-perceived constraints related to 
their former job, and the lack of moral support from 
work colleagues both limited and delayed return to 
work.
Our study has limitations particularly as it used a 
cross-sectional rather than a longitudinal survey design. 
In addition, as we asked participants to self-report on 
the impact of lymphedema over and above breast can-
cer, the study could be characterised by recall bias. How-
ever, a cross-sectional design and the use of an online 
survey allowed for a good sample size, and indicators of 
lymphoedema status were included, such as number of 
Table 2 Transition between employment after diagnosis of breast cancer or breast cancer and lymphedema
Breast cancer (BC) Breast cancer + lymphedema
209 152
When first diagnosed (%) Now (%) When first diagnosed (%) Now (%)
Paid employment 77 59 63 51
Yes, full-time 38 23 34 22
Yes, part-time 22 22 19 21
Yes, casual 7 8 3 2
Yes, self-employed 10 6 7 6
Not employed 22 41 37 49
No, looking for a job 0 3 1 3
No, retired 12 27 21 37
No, other 10 11 15 9
Total 100 100 100 100
Table 3 Transition between  employment after  diagnosis 
of breast cancer or lymphedema
Only includes participants who indicated that the diagnosis of breast cancer or 









No. % No. %
Yes, employment changed 84 51 20 19
Reduced working hours 39 23 10 10
Stopped working 27 16 5 5
Changed role 21 13 4 4
Changed employer 15 9 1 1
Self-employed now 3 2 2 2
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symptoms, time since diagnosis and we included only 
participants who had seen a lymphedema therapist. We 
did not examine education level and subsequent impact 
on work but previous studies have found that cancer 
survivors were likely to be unemployed if they did not 
complete high-school, were previously receiving social 
security benefits and women were 23 % less likely to find 
a job after they received employment assistance and sup-
port, such as job-hunting services or on-the-job training 
than men (Chan et al. 2008).
These limitations notwithstanding, this is the larg-
est study showing the impact of lymphedema over and 
above breast cancer, and shows how its impact worsens 
as the condition progresses. The issues are complicated 
and impact on work from an illness does depend on 
multiple competing factors. To adequately review these 
factors, we are planning a prospective study to fur-
ther differentiate the impact on work of lymphedema 
versus the impact of breast cancer and its short-term 
treatments.
The findings from this study have implications for 
clinical practice, future research and for policy makers. 
Health professionals involved in the care of women with 
lymphedema need to be aware that these women are at 
risk of not only experiencing psychological distress and 
body image disturbance (Alcorso et  al. 2016) but also 
additional detrimental effect of on women’s work and 
career, over and above the initial impact of breast cancer.





Told co-workers (n = 63; 61.2 %) Told supervisor (n = 49; 47.6 %)
Mean SD Somewhat 
agree (%)




Mean SD Somewhat 
agree (%)




















4.56 1.92 13 24 17 54 4.33 1.94 8 27 12 47




3.63 1.78 14 19 2 35 3.57 1.90 14 14 6 35
They were too 
busy to pay 
much atten-
tion
3.52 1.77 11 14 3 29 3.35 1.83 16 10 4 31
They did not 
trust my 
capabilities
2.41 1.44 5 3 0 8 2.39 1.58 4 0 4 8
They thought 
I used my 
condition as 
an excuse




1.94 1.37 2 2 2 5 2.31 1.79 8 0 6 14





2.05 1.52 3 3 2 8 2.43 1.88 10 2 6 18
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